Disc Medicine - Best comparison stock to Clinuvel, page-15

Cheers 007! I've remarked on a different thread for Cuv that it's an interesting comparison with Neu with Clinuvel looking at going alone and Neuren making a deal for Trof before Phase 3. Currently anyone would want to be in Neuren's position and we'll see what the future brings. My feeling with Clinuvel is that the company is so stretched getting Scenesse out there and at the same time hit the market with this broad range of future growth possibilities for melanocortins that they just continually don't deliver and the market has reacted accordingly. I feel the narrative is paring back to a focus on Scenesse sales and Vitiligo which will hopefully get things back on track. They just need to execute on those now even if it's at the expense of all the other promises. Continued sales growth this year and full enrolment in Cuv105 are the metrics that management need to deliver on and held to account over